Treatment
Somatic Epigenetic Silencing of RIPK3 Inactivates Necroptosis and Contributes to Chemoresistance in Malignant Mesothelioma
Clinical Cancer Research 2020 November 17 [Link] Yinfei Tan, Eleonora Sementino, Mitchell Cheung, Suraj Peri, Craig W Menges, Anna-Mariya Kukuyan, Ting Zhang, Vladimir Khazak, Lauren A Fox, Eric A Ross, Suresh Ramanathan, Suresh C Jhanwar, Raja M Flores, Siddharth Balachandran, Joseph R Testa Abstract Purpose: Receptor-interacting protein kinase RIPK3 phosphorylates effector molecule MLKL to trigger…
Read MoreHomozygous deletion of CDKN2A in malignant mesothelioma: Diagnostic utility, patient characteristics and survival in a UK mesothelioma centre
Lung Cancer 2020 November 5 [Link] Kelly Marshall, Susan Jackson, Jennifer Jones, Jayne Holme, Judith Lyons, Emma Barrett, Paul Taylor, Paul Bishop, Clare Hodgson, Michael Green, Nicholas Telford, Matthew Evison Abstract Background: Detection of homozygous deletion of the p16 gene (CDKN2A) by fluorescence in situ hybridization (FISH) has been investigated as an ancillary technique in…
Read MoreOncolytic herpesvirus therapy for mesothelioma – A phase I/IIa trial of intrapleural administration of HSV1716
Lung Cancer 2020 October 20 [Link] Sarah J Danson, Joe Conner, John G Edwards, Kevin G Blyth, Patricia M Fisher, Munitta Muthana, Abdulazeez Salawu, Fiona Taylor, Elizabeth Hodgkinson, Patrick Joyce, Jennifer Roman, Kathleen Simpson, Alexander Graham, Kirsty Learmonth, Penella J Woll Abstract Objectives: Malignant Pleural Mesothelioma (MPM) remains a major oncological challenge with limited therapeutic…
Read MoreImpact of metallothionein-knockdown on cisplatin resistance in malignant pleural mesothelioma
Scientific Reports 2020 October 29 [Link] Sabrina Borchert, Pia-Maria Suckrau, Robert F H Walter, Michael Wessolly, Elena Mairinger, Julia Steinborn, Balazs Hegedus, Thomas Hager, Thomas Herold, Wilfried E E Eberhardt, Jeremias Wohlschlaeger, Clemens Aigner, Agnes Bankfalvi, Kurt Werner Schmid, Fabian D Mairinger Abstract Malignant pleural mesothelioma (MPM) is a rare, but aggressive tumor with dismal…
Read MoreHeterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy
British Journal of Cancer 2020 October 26 [Link] Michael G White, Jefree J Schulte, Lai Xue, Yaniv Berger, Darryl Schuitevoerder, Charles C Vining, Hedy L Kindler, Aliya Husain, Kiran K Turaga, Oliver S Eng Abstract Programmed death-ligand 1 (PD-L1) expression has been described in patients with malignant peritoneal mesothelioma (MPM), but treatment strategies utilising immune…
Read MoreComplications and Predictive Factors for Air Leak > 10 Days with Neoadjuvant Chemotherapy Followed by Pleurectomy/Decortication for Malignant Pleural Mesothelioma
Annals of Surgical Oncology 2020 October [Link] Akifumi Nakamura, Nobuyuki Kondo, Toru Nakamichi, Masaki Hashimoto, Teruhisa Takuwa, Seiji Matsumoto, Kozo Kuribayashi, Takashi Kijima, Seiki Hasegawa Abstract Background: A few studies have reported the incidence and clinical implications of complications after pleurectomy/decortication (P/D). Objective: The aim of this study was to assess the details of complications…
Read MoreCRS/HIPEC with Major Organ Resection in Peritoneal Mesothelioma Does not Impact Major Complications or Overall Survival: A Retrospective Cohort Study of the US HIPEC Collaborative
Annals of Surgical Oncology 2020 October 18 [Link] David Roife, Benjamin D Powers, Mohammad Y Zaidi, Charles A Staley, Jordan M Cloyd, Ahmed Ahmed, Travis Grotz, Jennifer Leiting, Keith Fournier, Andrew J Lee, Jula Veerapong, Joel M Baumgartner, Callisia Clarke, Sameer H Patel, Ryan J Hendrix, Laura Lambert, Daniel E Abbott, Courtney Pokrzywa, Byrne Lee,…
Read MoreLocoregional control and toxicity after pleurectomy/decortication and intensity-modulated pleural radiation therapy in patients with malignant pleural mesothelioma
Thoracic Cancer 2020 October 8 [Link] Oscar Arrieta, Francisco Lozano-Ruiz, Monika Blake-Cerda, Rodrigo Catalán, Luis Lara-Mejía, Miguel Ángel Salinas, Federico Maldonado-Magos, José F Corona-Cruz Abstract Background: Treatment of malignant pleural mesothelioma (MPM) represents a major challenge for oncologists. Multimodality treatment, which generally involves induction chemotherapy, surgery and radiotherapy have recently shown promising results. The aim…
Read MoreThe phosphatase PTPN1/PTP1B is a candidate marker of better chemotherapy response in metastatic high-grade serous carcinoma
Cytopathology 2020 October 6 [Link] Ben Davidson, Annika Jøntvedt Bock, Arild Holth, Dag Andre Nymoen Abstract Objective: To analyze the expression and clinical role of the phosphatase PTPN1 (PTP1B) in serous effusions. Methods: PTPN1 mRNA expression by quantitative RT-PCR was analyzed in 83 high-grade serous carcinoma (HGSC) and 15 malignant mesothelioma (MM) effusions. PTP1B and…
Read MoreImmunotherapy for mesothelioma: rationale and new approaches
Clinical Advances for Hematology and Oncology 2020 September [Link] Joshua E Reuss, Patrick M Forde Abstract Therapeutic advancement for mesothelioma has been stagnant, with minimal treatment innovation in the past decade. Recently, however, immune checkpoint blockade (ICB) targeting the programmed death 1 and cytotoxic T-lymphocyte-associated antigen 4 pathways has revolutionized the treatment of multiple malignancies…
Read More